EC Microbiology

Literature Review Volume 18 Issue 8 - 2022

The Impact of Complication of COVID-19 - Associated Pulmonary Aspergillosis

Ahmad Aliyu*

Department of Microbiology, Ibrahim Badamasi Babangida University, Lapai, Niger State, Nigeria

*Corresponding Author: Ahmad Aliyu, Department of Microbiology, Ibrahim Badamasi Babangida University, Lapai, Niger State, Nigeria.
Received: June 26, 2022; Published: July 27, 2022

Background: Invasive Pulmonary Aspergillosis (IPA) is a secondary fungal infection that increasing the mortality rate and enhanced the concerns due to its detrimental effect among COVID-19 patients. Direct impairment to the airway epithelium is facilitated by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which allow the invasion of Aspergillus species.

Aim: The study aimed to evaluate the diagnostic criteria, incidence, risk factors and mortality rate that leads to the complication of COVID-19-associated pulmonary aspergillosis (CAPA) from the available data in the studies.

Method: A systemic literature review was carried out to evaluate all current epidemiology that reports the incidence of CAPA from relevant published articles.

Results: In critical ill COVID-19 patients, sputum and tracheal aspirate are usually positive but can represent upper airway colonization. Bronchoscopy with bronchoalveolar lavage is insignificant due to the risk of infection and nosocomial transmission among health care workers. Alternatively, CT-guide biopsies post mortem have been used more than autopsy and non-bronchoscopic lavage is usually preferred method for CAPA diagnosis when compared to bronchoalveolar lavage. The mortality rate is about 52/90 (58%) approximately and common comorbidities include diabetes mellitus, obesity, arterial hypertension, chronic respiratory failure, chronic obstructive pulmonary disease, chronic renal failure, bronchial asthma and cerebrovascular disease. Aspergillus fumigatus is a common causative agents of CAPA. Italy and UK had the highest mortality rate of 25.0% followed by Spain with 15.4% when compared to other locations.

Conclusion: Respiratory specimen is the most preferred invasive pulmonary aspergillosis (IPA) sample for fungal diagnostic examination. The detection of galactomannan does not prove tissue invasion and infection. The results of serum galactomannan is usually low in CAPA. Further studies on CAPA are needed urgently to differentiate between pulmonary and tracheobronchitis phenotypes of aspergillosis, immunological defense and host factors and to address the therapeutic options and appropriate diagnostic criteria of the infection.

Keywords: Invasive Pulmonary Aspergillosis; COVID-19; SARS-CoV-2; Aspergillus fumigatus; Galactomannan

  1. Guan WJ., et al. “Clinical characteristics of coronavirus disease 2019 in China”. New England Journal of Medicine 382 (2020): 1708-1720.
  2. Koehler P., et al. “Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance”. The Lancet Infectious Diseases 21 (2021): e149-162.
  3. Apostolopoulou A., et al. “Invasive pulmonary aspergillosis in patients with SARS-CoV-2 infection: a systematic review of the literature”. Diagnostics (Basel)10 (2020): 807.
  4. Mehta P., et al. “COVID-19: Consider cytokine storm syndromes and immunosuppression”. Lancet10229 (2020): 1033-1034.
  5. Donnelly JP., et al. “Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium”. Clinical Infectious Diseases 71 (2020): 1367-1376.
  6. Bartoletti M., et al. “Epidemiology of invasive pulmonary aspergillosis among COVID-19 intubated patients: a prospective study”. Clinical Infectious Diseases (2020).
  7. Short KR., et al. “Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions”. European Respiratory Journal 47 (2016): 954-966.
  8. Herold S., et al. “Influenza virus induced lung injury: pathogenesis and implications for treatment”. European Respiratory Journal 45 (2015): 1463-1478.
  9. Qin C., et al. “Dysregulation of immune response in patients with COVID-19 in Wuhan, China”. Clinical Infectious Diseases 71 (2020): 762-768.
  10. Dimopoulos G., et al. “COVID-19-Associated Pulmonary Aspergillosis (CAPA)”. Journal of Intensive Medicine 1 (2021): 71-80.
  11. Torrego A., et al. “Bronchoscopy in patients with COVID-19 with invasive mechanical ventilation: a single-center experience”. American Journal of Respiratory and Critical Care Medicine 202 (2020): 284-287.
  12. Wolfel R., et al. “Virological assessment of hospitalized patients with COVID-2019”. Nature 581 (2020): 465-469.
  13. Bullard J., et al. “Predicting infectious SARS-CoV-2 from diagnostic samples”. Clinical Infectious Diseases (2020).
  14. Zhang H., et al. “Histopathologic changes and SARS-CoV-2 immunostaining in the lung of a patient with COVID-19”. Annals of Internal Medicine 172 (2020): 629-632.
  15. White PL., et al. “A national strategy to diagnose COVID-19 associated invasive fungal disease in the ICU”. Clinical Infectious Diseases7 (2020): e1634-1644.
  16. Wang J., et al. “Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series”. Critical Care1 (2020): 299.
  17. Chauvet P., et al. “Risk factors for invasive pulmonary aspergillosis in critically ill patients with coronavirus disease 2019-induced acute respiratory distress syndrome”. Critical Care Explorations11 (2020): e0244.
  18. Koehler P., et al. “COVID-19 associated pulmonary aspergillosis”. Mycoses6 (2020): 528-534.
  19. Santana MF., et al. “Confirmed invasive pulmonary aspergillosis and COVID-19: the value of postmortem findings to support antemortem management”. Revista da Sociedade Brasileira de Medicina Tropical 53 (2020): e20200401.
  20. Flikweert AW., et al. “Late histopathologic characteristics of critically ill COVID-19 patients: different phenotypes without evidence of invasive aspergillosis, a case series”. Journal of Critical Care 59 (2020): 149-155.
  21. Razazi K., et al. “Risks of ventilator-associated pneumonia and invasive pulmonary Aspergillosis in patients with viral acute respiratory distress syndrome related or not to Coronavirus 19 disease”. Critical Care1 (2020): 699.
  22. Prattes J., et al. “Invasive pulmonary aspergillosis complicating COVID-19 in the ICU - a case report”. Medical Mycology Case Reports 31 (2021): 2-5.
  23. Nasir N., et al. “COVID-19-associated pulmonary aspergillosis (CAPA) in patients admitted with severe COVID-19 pneumonia: an observational study from Pakistan”. Mycoses8 (2020): 766-770.
  24. Mohamed A., et al. “Multi-triazole-resistant Aspergillus fumigatus and SARS-CoV-2 co-infection: a lethal combination”. Medical Mycology Case Reports 31 (2021): 11-14.
  25. Helleberg M., et al. “Invasive aspergillosis in patients with severe COVID-19 pneumonia”. Clinical Microbiology Infection1 (2021): 147-148.
  26. Machado M., et al. “Invasive pulmonary aspergillosis in the COVID-19 era: an expected new entity”. Mycoses2 (2021): 132-143.
  27. Lamoth F., et al. “Incidence of invasive pulmonary aspergillosis among critically ill COVID-19 patients”. Clinical Microbiology and Infection12 (2020): 1706-1708.
  28. Rutsaert L., et al. “COVID-9-associated invasive pulmonary aspergillosis”. Annals of Intensive Care1 (2020): 71.
  29. Patti RK., et al. “Subacute aspergillosis “fungal balls” complicating COVID-19”. Journal of Investigative Medicine High Impact Case Reports 8 (2020): 2324709620966475.
  30. Schein F., et al. “Fatal aspergillosis complicating severe SARS-CoV-2 infection: a case report”. Journal of Medical Mycology4 (2020): 101039.
  31. Heldt S and Hoenigl M. “Lateral flow assays for the diagnosis of invasive aspergillosis: Current status”. Current Fungal Infection Reports2 (2017): 45-51.
  32. Meijer EFJ., et al. “Azole-resistant COVID-19- associated pulmonary aspergillosis in an immuno competent host: a case report”. Journal of Fungi (Basel)2 (2020): 79.
  33. Arastehfar A., et al. “COVID-19 associated pulmonary aspergillosis (CAPA)-from immunology to treatment”. Journal of Fungi (Basel)2 (2020): 91.
  34. Verweij PE., et al. “Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion”. Intensive Care Medicine8 (2020): 1524-1535.
  35. Verweij PE., et al. “Diagnosing COVID-19-associated pulmonary aspergillosis”. The Lancet Microbe2 (2020): e53-e55.
  36. Hoenigl M. “Invasive fungal disease complicating COVID-19: when it rains it pours”. Clinical Infectious Diseases7 (2020): e1645-e16448.
  37. Kyrmizi I., et al. “Corticosteroids block autophagy protein recruitment in Aspergillus fumigatus phagosomes via targeting dectin-1/Syk kinase signaling”. The Journal of Immunology3 (2013): 1287-1299.
  38. Wiederhold NP and Verweij PE. “Aspergillus fumigatus and pan-azole resistance: who should be concerned”. Current Opinion in Infectious Diseases4 (2020): 290-297.
  39. Wahidi MM., et al. “American Association for Bronchology and Interventional Pulmonology (AABIP) statement on the use of bronchoscopy and respiratory specimen collection in patients with suspected or confirmed COVID-19 infection”. Journal of Bronchology and Interventional Pulmonology 27 (2020): e52-e54.
  40. Koehler P., et al. “Intensive care management of influenza-associated pulmonary aspergillosis”. Clinical Microbiology and Infection 25 (2019): 1501-1509.

Ahmad Aliyu. The Impact of Complication of COVID-19 - Associated Pulmonary Aspergillosis.EC Microbiology 18.8 (2022): 65-76.